These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29363454)

  • 1. Effect of Health Care on Quality of Life among Human Immunodeficiency Virus Infected Adults With and Without Visceral Leishmaniasis in northwest Ethiopia: A Longitudinal Follow-Up Study.
    Alemayehu M; Wubshet M; Mesfin N; Gebayehu A
    Am J Trop Med Hyg; 2018 Mar; 98(3):747-752. PubMed ID: 29363454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life of HIV infected adults with and without Visceral Leishmaniasis in Northwest Ethiopia.
    Alemayehu M; Wubshet M; Mesfin N; Tamiru A; Gebayehu A
    Health Qual Life Outcomes; 2017 Aug; 15(1):65. PubMed ID: 28851361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change in quality of life: a follow up study among patients with HIV infection with and without TB in Ethiopia.
    Deribew A; Deribe K; Reda AA; Tesfaye M; Hailmichael Y; Maja T; Colebunders R
    BMC Public Health; 2013 Apr; 13():408. PubMed ID: 23627925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do common mental disorders decline over time in TB/HIV co-infected and HIV patients without TB who are on antiretroviral treatment?
    Deribew A; Deribe K; Reda AA; Tesfaye M; Hailmichael Y; Maja T
    BMC Psychiatry; 2013 Jun; 13():174. PubMed ID: 23802647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perceived quality of life among Visceral Leishmaniasis and HIV coinfected migrant male-workers in Northwest Ethiopia: a qualitative study.
    Alemayehu M; Wubshet M; Mesfin N; Gebayehu A
    BMC Public Health; 2017 Feb; 17(1):204. PubMed ID: 28209209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of Human Immunodeficiency Virus and associated factors among Visceral Leishmaniasis infected patients in Northwest Ethiopia: a facility based cross-sectional study.
    Alemayehu M; Wubshet M; Mesfin N; Gebayehu A
    BMC Infect Dis; 2017 Feb; 17(1):152. PubMed ID: 28212625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does timing of antiretroviral treatment influence treatment outcomes of visceral leishmaniasis in Northwest Ethiopia?
    Aderie EM; Diro E; Zachariah R; da Fonseca MS; Abongomera C; Dolamo BL; Ritmeijer K
    Trans R Soc Trop Med Hyg; 2017 Mar; 111(3):107-116. PubMed ID: 28633331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
    Abongomera C; Diro E; de Lima Pereira A; Buyze J; Stille K; Ahmed F; van Griensven J; Ritmeijer K
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006527. PubMed ID: 29799869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visceral leishmaniasis treatment outcome and its determinants in northwest Ethiopia.
    Welay GM; Alene KA; Dachew BA
    Epidemiol Health; 2016; 39():e2017001. PubMed ID: 28092934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Risk and Predictors of Visceral Leishmaniasis Relapse in Human Immunodeficiency Virus-Coinfected Patients in Ethiopia: A Retrospective Cohort Study.
    Abongomera C; Diro E; Vogt F; Tsoumanis A; Mekonnen Z; Admassu H; Colebunders R; Mohammed R; Ritmeijer K; van Griensven J
    Clin Infect Dis; 2017 Oct; 65(10):1703-1710. PubMed ID: 29020196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India.
    Mahajan R; Das P; Isaakidis P; Sunyoto T; Sagili KD; Lima MA; Mitra G; Kumar D; Pandey K; Van Geertruyden JP; Boelaert M; Burza S
    Clin Infect Dis; 2015 Oct; 61(8):1255-62. PubMed ID: 26129756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visceral leishmaniasis and leishmaniasis-HIV coinfection: comparative study.
    Coutinho JVSC; Santos FSD; Ribeiro RDSP; Oliveira IBB; Dantas VB; Santos ABFS; Tauhata JR
    Rev Soc Bras Med Trop; 2017; 50(5):670-674. PubMed ID: 29160515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.
    Sinha PK; van Griensven J; Pandey K; Kumar N; Verma N; Mahajan R; Kumar P; Kumar R; Das P; Mitra G; Flevaud L; Ferreyra C; Remartinez D; Pece M; Palma PP
    Clin Infect Dis; 2011 Oct; 53(7):e91-8. PubMed ID: 21890763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Clinical Outcomes in Visceral Leishmaniasis/Human Immunodeficiency Virus-Coinfected Patients During and After Pentamidine Secondary Prophylaxis in Ethiopia: A Single-Arm Clinical Trial.
    Diro E; Ritmeijer K; Boelaert M; Alves F; Mohammed R; Abongomera C; Ravinetto R; De Crop M; Fikre H; Adera C; van Loen H; Tsoumanis A; Adriaensen W; Hailu A; Griensven JV
    Clin Infect Dis; 2018 Jan; 66(3):444-451. PubMed ID: 29020217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.
    ter Horst R; Collin SM; Ritmeijer K; Bogale A; Davidson RN
    Clin Infect Dis; 2008 Jun; 46(11):1702-9. PubMed ID: 18419422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with relapse and hospital death in patients coinfected with visceral leishmaniasis and HIV: a longitudinal study.
    Costa LDLN; Lima US; Rodrigues V; Lima MIS; Silva LA; Ithamar J; Azevedo CMPS
    BMC Infect Dis; 2023 Mar; 23(1):141. PubMed ID: 36882732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visceral Leishmaniasis and HIV Co-Infection in Northwest Ethiopia: Antiretroviral Treatment and Burden of Disease among Patients Enrolled in HIV Care.
    van Griensven J; Simegn T; Endris M; Diro E
    Am J Trop Med Hyg; 2018 Feb; 98(2):486-491. PubMed ID: 29210347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visceral leishmaniasis as an independent cause of high immune activation, T-cell senescence, and lack of immune recovery in virologically suppressed HIV-1-coinfected patients.
    Casado JL; Abad-Fernández M; Moreno S; Pérez-Elías MJ; Moreno A; Bernardino JI; Vallejo A
    HIV Med; 2015 Apr; 16(4):240-8. PubMed ID: 25604328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life in patients with human immunodeficiency virus infection: impact of social support, coping style and hopelessness.
    Swindells S; Mohr J; Justis JC; Berman S; Squier C; Wagener MM; Singh N
    Int J STD AIDS; 1999 Jun; 10(6):383-91. PubMed ID: 10414881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life perceptions amongst patients co-infected with Visceral Leishmaniasis and HIV: A qualitative study from Bihar, India.
    Nair M; Kumar P; Pandey S; Kazmi S; Moreto-Planas L; Ranjan A; Burza S
    PLoS One; 2020; 15(2):e0227911. PubMed ID: 32040525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.